Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Amrinone |
EINECS | 262-390-0 |
CAS No. | 60719-84-8 | Density | 1.277 g/cm3 |
PSA | 71.77000 | LogP | 1.60030 |
Solubility | Insoluble in water or chloroform. Slightly soluble in acetic acid or DMF. Soluble in DMSO | Melting Point |
294-297 °C (dec.) |
Formula | C10H9N3O | Boiling Point | 451.5 °C at 760 mmHg |
Molecular Weight | 187.201 | Flash Point | 226.9 °C |
Transport Information | UN 2811 6.1/PG 3 | Appearance | Crystalline solid |
Safety | 28-45-36-26 | Risk Codes | 25-36/37/38-20/21/22 |
Molecular Structure | Hazard Symbols | T, Xn | |
Synonyms |
3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone;Amrinone (TN);Prestwick_44;Wincoram;5-Amino-(3,4-bipyridin)-6(1H)-one;Cordemcura;(3,4-Bipyridin)-6(1h)-one, 5-amino-;Amrinona [INN-Spanish];5-25-15-00181 (Beilstein Handbook Reference);Amrinonum [INN-Latin];Amrinone [USAN:BAN:INN];Inamrinone;Inamrinone (USP);[3,4'-Bipyridin]-6(1H)-one,5-amino-;Inocor;3-amino-5-pyridin-4-yl-1H-pyridin-2-one;Amrinone (JAN);5-amino-3,4′-bipyridin-6(1H)-one;5-Amino-5-(4-pyridinyl)-2(1 h)-pyridinone; |
Article Data | 6 |
The molecular Structure of Amrinone(CAS NO.60719-84-8):
IUPAC Name: 3-amino-5-pyridin-4-yl-1H-pyridin-2-one
Empirical Formula: C10H9N3O
Molecular Weight: 187.198
H bond acceptors: 4
H bond donors: 3
Freely Rotating Bonds: 2
Index of Refraction: 1.625
Molar Refractivity: 51.82 cm3
Molar Volume: 146.5 cm3
Surface Tension: 56 dyne/cm
Density: 1.277 g/cm3
Flash Point: 226.9 °C
Enthalpy of Vaporization: 71.06 kJ/mol
Boiling Point: 451.5 °C at 760 mmHg
Vapour Pressure: 2.42E-08 mmHg at 25°C
Melting Point: 294-297°C (dec.)
Storage temp. 2-8°C
InChI
InChI=1/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)
Smiles
c1(c2ccncc2)cc(c(=O)[nH]c1)N
EINECS: 262-390-0
Product Categories: Active Pharmaceutical Ingredients;Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; Calcium channel
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 3mg/kg/15M-I (3mg/kg) | BLOOD: THROMBOCYTOPENIA | Clinical Pharmacology and Therapeutics Vol. 53, Pg. 661, 1993. |
dog | LDLo | intravenous | 120mg/kg (120mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 1117, 1990. |
man | LDLo | oral | 1429ug/kg (1.429mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) LIVER: LIVER FUNCTION TESTS IMPAIRED BLOOD: THROMBOCYTOPENIA | Archives of Internal Medicine. Vol. 145, Pg. 825, 1985. |
mouse | LD50 | intravenous | 150mg/kg (150mg/kg) | Trends in Pharmacological Sciences. Vol. 1, Pg. 143, 1980. | |
mouse | LD50 | oral | 288mg/kg (288mg/kg) | Trends in Pharmacological Sciences. Vol. 1, Pg. 143, 1980. | |
mouse | LD50 | subcutaneous | 212mg/kg (212mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 1111, 1990. |
rabbit | LD50 | oral | 286mg/kg (286mg/kg) | Pharmazie. Vol. 41, Pg. 209, 1986. | |
rat | LD50 | intravenous | 75mg/kg (75mg/kg) | Pharmazie. Vol. 41, Pg. 209, 1986. | |
rat | LD50 | oral | 102mg/kg (102mg/kg) | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 259, 1983. | |
rat | LD50 | subcutaneous | 150mg/kg (150mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 1111, 1990. |
Poison by ingestion and intravenous routes. Human systemic effects by ingestion: cardiac arrhythmias, liver function, thrombocytopenia. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx. A cardiotonic agent.
Hazard Codes: T,Xn
Risk Statements: 25-36/37/38-20/21/22
R25 :Toxic if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 28-45-36-26
S28:After contact with skin, wash immediately with plenty of soap-suds.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36:Wear suitable protective clothing.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: DW2500000
HazardClass: 6.1(b)
PackingGroup: III
Amrinone , with CAS number of 60719-84-8, can be called (3,4'-Bipyridin)-6(1H)-one, 5-amino- ; [3,4'-bipyridin]-6(1H)-one, 5-amino- ; [3,4'-bipyridin]-6-ol, 5-amino- ; 5-Amino-3,4'-bipyridin-6(1H)-one ; 5-Amino-3,4'-bipyridin-6-ol ; 262-390-0 [EINECS/ELINCS] . Amrinone(CAS NO.60719-84-8) may increase myocardial ischemia. Blood pressure, pulseand EKG should be constantly monitored. Amrinone should only be diluted with normal saline or 1/2 normal saline; no dextrose solutions should be used. Furosemide should not be administered into an IV line delivering Amrinone. It is used in the treatment of congestive heart failure and has been studied for use before coronary artery bypass surgery.